B

BioNTech

Pioneering Individualized Medicine

Mainz, Germany (US: Cambridge, MA)
5,500+

About BioNTech

Industry: Biotechnology
Founded: 2008
Founders: Ugur Sahin, Ozlem Tureci
Status: Public (NASDAQ: BNTX)

Funding & Growth

Total Raised: $1.5B+
Valuation: $25B+ market cap
Stage: Public
Key Investors:
Pfizer partnership Public markets

✓ Pros

  • • mRNA technology pioneer
  • • Strong COVID vaccine success
  • • Heavy oncology pipeline investment
  • • Cambridge, MA hub
  • • Founder-led scientific culture

✗ Cons

  • • German headquarters (timezone)
  • • Post-COVID transition challenges
  • • Fast-paced, demanding
  • • High expectations

Get weekly job alerts